Adalimumab Biosimilar Market – Global Industry Analysis and Forecast (2022-2029)

Adalimumab Biosimilar Market is expected to reach US$ 2.85 Bn. at a CAGR of 17.6% during the forecast period 2029.
Biosimilar is also called as subsequent entry biologics or follow-on biologics. Adalimumab is a medicine used to treat psoriatic arthritis, rheumatoid arthritis, and various other diseases. Adalimumab biosimilar is equally effective and safe in reducing inflammation as Humira.

Adalimumab Biosimilar Market – Global Industry Analysis and Forecast (2022-2029)

Adalimumab Biosimilar Market is expected to reach US$ 2.85 Bn. at a CAGR of 17.6% during the forecast period 2029.The report study has analyzed the revenue impact of the COVID-19 pandemic on the sales revenue of market leaders, market followers, and market disrupters in the report, and the same is reflected in our analysis.